We report the discovery of novel small molecule inhibitors of platelet-type 12-human lipoxygenase, which display nanomolar activity against the purified enzyme, using a quantitative high-throughput screen (qHTS) on a library of 153607 compounds. These compounds also exhibit excellent specificity, >50-fold selectivity vs the paralogues, 5-human lipoxygenase, reticulocyte 15-human lipoxygenase type-1, and epithelial 15-human lipoxygenase type-2, and >100-fold selectivity vs ovine cyclooxygenase-1 and human cyclooxygenase-2. Kinetic experiments indicate this chemotype is a noncompetitive inhibitor that does not reduce the active site iron. Moreover, chiral HPLC separation of two of the racemic lead molecules revealed a strong preference for the (-)-enantiomers (IC(50) of 0.43 ± 0.04 and 0.38 ± 0.05 μM) compared to the (+)-enantiomers (IC(50) of >25 μM for both), indicating a fine degree of selectivity in the active site due to chiral geometry. In addition, these compounds demonstrate efficacy in cellular models, which underscores their relevance to disease modification.
We report the discovery of novel small molecule inhibitors of platelet-type 12-class="Species">humann class="Gene">lipoxygenase, which display nanomolar activity against the purified enzyme, using a quantitative high-throughput screen (qHTS) on a library of 153607 compounds. These compounds also exhibit excellent specificity, >50-fold selectivity vs the paralogues, 5-humanlipoxygenase, reticulocyte 15-humanlipoxygenase type-1, and epithelial 15-humanlipoxygenase type-2, and >100-fold selectivity vs ovine cyclooxygenase-1 and humancyclooxygenase-2. Kinetic experiments indicate this chemotype is a noncompetitive inhibitor that does not reduce the active site iron. Moreover, chiral HPLC separation of two of the racemic lead molecules revealed a strong preference for the (-)-enantiomers (IC(50) of 0.43 ± 0.04 and 0.38 ± 0.05 μM) compared to the (+)-enantiomers (IC(50) of >25 μM for both), indicating a fine degree of selectivity in the active site due to chiral geometry. In addition, these compounds demonstrate efficacy in cellular models, which underscores their relevance to disease modification.
Authors: V E Steele; C A Holmes; E T Hawk; L Kopelovich; R A Lubet; J A Crowell; C C Sigman; G J Kelloff Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-05 Impact factor: 4.254
Authors: Jaime L Masferrer; Ben S Zweifel; Medora Hardy; Gary D Anderson; Dawn Dufield; Luz Cortes-Burgos; Robert A Pufahl; Matthew Graneto Journal: J Pharmacol Exp Ther Date: 2010-04-08 Impact factor: 4.030
Authors: Adriana L Gonzalez; Richard L Roberts; Pierre P Massion; Sandra J Olson; Yu Shyr; Scott B Shappell Journal: Hum Pathol Date: 2004-07 Impact factor: 3.466
Authors: Reheman Adili; Benjamin E Tourdot; Katherine Mast; Jennifer Yeung; John C Freedman; Abigail Green; Diane K Luci; Ajit Jadhav; Anton Simeonov; David J Maloney; Theodore R Holman; Michael Holinstat Journal: Arterioscler Thromb Vasc Biol Date: 2017-08-03 Impact factor: 8.311
Authors: Diane K Luci; J Brian Jameson; Adam Yasgar; Giovanni Diaz; Netra Joshi; Auric Kantz; Kate Markham; Steve Perry; Norine Kuhn; Jennifer Yeung; Edward H Kerns; Lena Schultz; Michael Holinstat; Jerry L Nadler; David A Taylor-Fishwick; Ajit Jadhav; Anton Simeonov; Theodore R Holman; David J Maloney Journal: J Med Chem Date: 2014-01-06 Impact factor: 7.446
Authors: Y Imai; A D Dobrian; J R Weaver; M J Butcher; B K Cole; E V Galkina; M A Morris; D A Taylor-Fishwick; J L Nadler Journal: Diabetes Obes Metab Date: 2013-09 Impact factor: 6.577
Authors: Sarah A Tersey; Bernhard Maier; Yurika Nishiki; Aarthi V Maganti; Jerry L Nadler; Raghavendra G Mirmira Journal: Mol Cell Biol Date: 2014-07-28 Impact factor: 4.272
Authors: Ann M Gregus; Darren S Dumlao; Spencer C Wei; Paul C Norris; Laura C Catella; Flore G Meyerstein; Matthew W Buczynski; Joanne J Steinauer; Bethany L Fitzsimmons; Tony L Yaksh; Edward A Dennis Journal: FASEB J Date: 2013-02-04 Impact factor: 5.191